Overview

RSHF in Colorectal Cancer

Status:
Completed

Trial end date:
2018-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to study stereotactic radiotherapy with a dose of 40 Gy in 4 fractions over 2 weeks with concomitant 40 mg/m2 of irinotecan (1st and 3rd irradiation session).

Phase:

Phase 2

Details

Lead Sponsor:

Institut Cancerologie de l'Ouest

Treatments:

Irinotecan